• About
  • Blog
  1. Home
  2. Blog
  3. Companies
  4. LLY

Eli Lilly and Company(LLY)

New York Stock Exchange
Sector: Healthcare | Industry: Drug Manufacturers - General
Eli Lilly and Company logo

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Latest News & Analysis

Group of scientists in lab coats collaborating in a high-tech laboratory with a purple-themed background
Jun 13, 2025

Eli Lilly (LLY): Q4 2024 Earnings, GLP-1 Safety, and Strategic Growth

Eli Lilly's stock surged past $812, fueled by strong financial performance and strategic moves despite new GLP-1 safety concerns. We analyze its growth, R&D, and market positioning.

Read more →
Visual representation of Eli Lilly's exceptional 2024 financial performance, showcasing over 100% net income surge and 32% revenue growth driven by pharmaceutical innovation and strategic investments in GLP-1 treatments, reinforcing market leadership.
Jun 12, 2025

Eli Lilly's 2025 Financials: Growth, Strategy, and GLP-1 Dynamics

Eli Lilly's strategic moves in 2025, from robust financial performance and pipeline expansion to navigating GLP-1 safety concerns and innovative AI collaborations.

Read more →
Eli Lilly's 2025 Strategy: Clinical Data, Regulation, and Financials
Jun 11, 2025

Eli Lilly's 2025 Strategy: Clinical Data, Regulation, and Financials

Eli Lilly navigates strategic collaborations, clinical data readouts, and regulatory shifts in 2025, driving significant financial and market movements.

Read more →
Eli Lilly's Financial Strength and Strategic Growth in 2025
Jun 5, 2025

Eli Lilly's Financial Strength and Strategic Growth in 2025

Eli Lilly's strategic moves in oncology and cardiometabolic health, coupled with strong financial performance, position it for continued growth.

Read more →
Abstract graphic showing a sharp upward trend line and interwoven geometric shapes in shades of purple, representing Eli Lilly's significant financial growth, doubled net income, and strategic investments in manufacturing and pipeline expansion.
May 28, 2025

Eli Lilly's Explosive Growth and Strategic Maneuvers (LLY)

Eli Lilly's 2024 financial results showed explosive growth, driven by strategic investments and pipeline success. Learn how recent acquisitions, regulatory milestones, and industry trends impact LLY.

Read more →
Eli Lilly (LLY) stock analysis: Navigating market shifts, regulatory hurdles, and competitive landscape while capitalizing on growth opportunities in obesity and heart disease treatments.
Apr 9, 2025

Eli Lilly (LLY): Regulatory Challenges and Growth Opportunities

Eli Lilly (LLY) navigates regulatory changes, market competition, and healthcare policies. Key is Lepodisiran, a therapy that reduces heart disease risk, positioning it for growth.

Read more →
Eli Lilly stock analysis: Zepbound lawsuits, tariff risks, and future growth prospects for LLY investors.
Apr 2, 2025

Eli Lilly (LLY): Zepbound Lawsuits, Tariffs, and Growth

Eli Lilly (LLY) navigates Zepbound lawsuits, tariff risks, and promising drug developments. A detailed analysis for investors.

Read more →
Eli Lilly (LLY) stock analysis: Alzheimer's setback, weight-loss drug hope, and LillyDirect market expansion.
Mar 28, 2025

Eli Lilly (LLY): Alzheimer's Setback, Weight-Loss Hope

Eli Lilly (LLY) navigates EU rejection of Kisunla, promising weight-loss drug Orforglipron, LillyDirect expansion, and VIG ETF inclusion amid macroeconomic challenges.

Read more →
Eli Lilly's strategic moves in obesity and diabetes treatment market: acquisitions, competition, and R&D investments.
Mar 25, 2025

Eli Lilly (LLY): Strategic Moves, Obesity Drug Race, and Future Outlook

Eli Lilly navigates the obesity drug race with strategic acquisitions and awaits Orforglipron trial results, shaping its competitive future against Novo Nordisk.

Read more →
Eli Lilly stock performance, obesity drug market, and AI-driven drug discovery analysis.
Mar 24, 2025

Eli Lilly (LLY): Obesity Drugs, AI Innovation, and Growth Analysis

Eli Lilly's strategic moves in obesity drugs, AI, and global expansion drive growth. Financial analysis reveals strong revenue and net income growth, but high valuation warrants caution.

Read more →
Eli Lilly's strategic expansion with Mounjaro in India: financial growth, R&D investments, and market competition analysis. LLY stock forecast.
Mar 21, 2025

Eli Lilly: Mounjaro's India Launch, Financial Growth, and R&D

Eli Lilly's Mounjaro launches in India, financial growth surges, and R&D investments drive innovation. Investor confidence remains strong amid competitive dynamics.

Read more →
Eli Lilly (LLY) stock analysis: Market volatility, competitive landscape, and growth opportunities for investors.
Mar 18, 2025

Eli Lilly (LLY): Market Volatility and Competitive Pressures

Eli Lilly (LLY) navigates market volatility with competitive pressures from AbbVie in obesity and potential drug pricing regulations, balanced by breakthroughs in dermatology.

Read more →
Eli Lilly's dermatology advancements, GLP-1 market dominance with Zepbound and Mounjaro, and the future of healthcare innovation; analyze LLY's stock, financials, and strategic outlook.
Mar 10, 2025

Eli Lilly (LLY): GLP-1 Dominance and Dermatology Innovations

Eli Lilly (LLY) is experiencing growth and innovation across its pharmaceutical portfolio. Dermatology breakthroughs, GLP-1 dominance, and LillyDirect highlight its strategic direction.

Read more →
Eli Lilly's manufacturing expansion, Zepbound pricing strategies, GLP-1 market competition, and growth potential analysis.
Mar 5, 2025

Eli Lilly (LLY) News: Manufacturing, Pricing, and Growth Analysis

Eli Lilly is expanding manufacturing, innovating Zepbound pricing, and competing in the GLP-1 market. Jaypirca's EU approval and ad campaigns against unapproved drugs highlight strategic moves.

Read more →
Eli Lilly's Manufacturing Expansion and Jaypirca Approval: Analyzing the pharmaceutical giant's strategic moves and growth prospects in diabetes, weight loss, and oncology.
Feb 28, 2025

Eli Lilly's $27B US Manufacturing Push & Jaypirca's EU Approval

Eli Lilly expands US manufacturing with a $27B investment amid rising demand for Zepbound & Mounjaro. Plus, Jaypirca receives positive EU recommendation.

Read more →
Eli Lilly invests $27B in US manufacturing: Explore the impact of tariffs, Zepbound, Mounjaro, and competition with Novo Nordisk. Stay informed on pharma reshoring and market share forecasts.
Feb 27, 2025

Eli Lilly's $27B US Investment: Tariffs, Zepbound, and Pharma Reshoring

Eli Lilly's $27B US investment signals a strategic shift amid rising demand for Zepbound and Mounjaro, addressing tariffs and bolstering supply chain resilience.

Read more →
Eli Lilly's Zepbound: Pricing strategies, competition with Novo Nordisk, direct-to-consumer access, and future growth prospects in the weight-loss drug market.
Feb 26, 2025

Eli Lilly's Zepbound Strategy: Pricing, Competition, Growth

Eli Lilly strategically adjusts Zepbound pricing, navigates competition with Novo Nordisk, and expands access via LillyDirect. The company's R&D pipeline extends beyond weight loss.

Read more →
Eli Lilly's Zepbound strategy: Analyzing price cuts, competition with Novo Nordisk, and direct-to-consumer initiatives.
Feb 25, 2025

Eli Lilly's Zepbound Strategy: Navigating Competition and Policy Risks

Eli Lilly strategically navigates the GLP-1 market with Zepbound price adjustments and LillyDirect, facing competition from Novo Nordisk and policy risks.

Read more →
Eli Lilly growth strategy: Pipeline, weight loss drugs, and AI impact for 2025.
Feb 24, 2025

Eli Lilly's 2025 Growth Strategy: Pipeline, Weight Loss & AI Impact

Eli Lilly navigates 2025 with GLP-1 therapies, strategic R&D investments, and expansion into new therapeutic areas, demonstrating innovation and long-term value creation.

Read more →
Eli Lilly's strategic shift towards Alzheimer's and ALS research, driven by GLP-1 success. Investment analysis and market impact.
Feb 24, 2025

Eli Lilly's Bold Moves: Weight Loss, Alzheimer's, and the Future

Eli Lilly strategically shifts to Alzheimer's and ALS, leveraging GLP-1 success. A $550M weight-loss pill investment and projected 32% revenue growth highlight potential.

Read more →
Eli Lilly stock analysis: Strategic shift from weight loss drugs to neurological treatments impacting LLY stock.
Feb 21, 2025

Eli Lilly's Strategic Shift: Weight Loss Windfall Fuels Alzheimer's and ALS Push

Eli Lilly leverages its weight loss drug success to invest in groundbreaking Alzheimer's and ALS research, driving a strategic pivot.

Read more →
Eli Lilly logo displayed against a modern laboratory backdrop.
Feb 18, 2025

Eli Lilly's GLP-1 Drugs: A Market-Shaping Force in 2025

This comprehensive analysis examines Eli Lilly's GLP-1 drugs market impact, strategic developments, and future growth opportunities.

Read more →
Futuristic pharmaceutical lab with glowing GLP-1 molecule, symbolizing innovation and market leadership.
Feb 14, 2025

Eli Lilly's GLP-1 Drugs Fuel Growth Amid Competitive Pressure

Latest analysis reveals Eli Lilly’s strategic GLP-1 focus and diversified R&D, driving robust revenue growth and future potential.

Read more →

Professional-grade financial analysis tools for informed investment decisions.

Product

  • Features
  • Pricing

Resources

  • Blog
  • Knowledge Base
  • Community
  • Market Data

Company

  • About
  • Careers
  • Contact
  • Partners

Legal

  • Privacy
  • Terms
  • License
  • Security

© 2025 Monexa. All rights reserved. Market data provided by financial exchanges and may be delayed as specified by financial exchanges or our data providers.